Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : analysts and calls -- B of A -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (3)	9/25/2002 8:59:10 AM
From: scaram(o)uche	Respond to of 33

At one time, their name was Oncogene Sciences. They changed their name, to OSI, to illustrate their intense interest in non-cancer areas, their breadth of projects. That wasn't long ago. Listen to their recent presentation at Bear Stearns, where Goddard brags of their exclusive preclinical interest in cancer, going forward! I feel that they got a bunch of mediocre (and some difficult!) projects from GILD, that GILD really took them. Read about five 10-Ks, going back. Infectious diseases? Asthma? Tarceva derived from one of biotech's early deals. The work in collaboration with Pfizer was impressive, for more than just Tarceva. But the return of Tarceva wasn't strategy, and otherwise it's been a "stand up" act.

To: Icebrg who wrote (3)	10/15/2002 12:15:52 PM
From: Icebrg	Read Replies (2) \| Respond to of 33

RESEARCH ALERT-Banc of America starts biopharmaceuticals Tuesday October 15, 11:58 am ET CHICAGO, Oct 15 (Reuters) - Banc of America Securities on Tuesday said it started coverage of biopharmaceutical firms Cephalon Inc. (CEPH) and IDEC Pharmaceuticals Corp. (IDPH) with "buy" ratings and started Genzyme General Corp. (GENZ) and Chiron Corp.(CHIR) at "market performer." "Cephalon is a high growth, profitable biopharmaceutical company with three marketed drugs," analyst Michael King said in a research note. He set a $59 one-year price target on the stock, which closed Monday at $44.86 on the Nasdaq. He said IDEC is a leader among large-capitalization profitable biotechnology companies and projected a 23.1 percent five-year compound earnings per share growth rate, which he called conservative. He also set a $50 one-year price target on the stock, which closed at $39.21 on the Nasdaq. Genzyme will have to bring down excessive inventories that have built up over the past several quarters, King said. "Although (Genzyme) trades at an appreciable discount to the group, we remain on the sidelines as we wait for Renagel growth to re-accelerate and additional clarity regarding the timing of approval for" the company's enzyme-replacement therapy products. As for Chiron, King said its projected growth rate is the second lowest in the group of profitable biotech companies.